Fox Foundation backs Parkinson's biomarker projects; Researchers ID breast cancer biomarker;

> The Michael J. Fox Foundation for Parkinson's Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson's disease. Release

> University of Arizona researchers are part of an international team that has discovered a new cellular mechanism that is associated with the development of breast cancer. Release

> A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how Velcade, the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. Researchers demonstrated that biomarkers might help guide the selection of patients for clinical trials and speed-up the development of targeted cancer drugs. Release

> BG Medicine a biomarker discovery and in vitro diagnostics company, announced today the publication of The BioImage Study trial design and key objectives in the American Heart Journal. Release

> Researchers have discovered a biomarker called human beta defensin-3 (hBD-3), which may help in early detection of oral cancer. Story

> OvaGene Oncology, a biotech company specializing in the development of personalized DNA-based diagnostics for gynecologic cancer, has inked license agreements with key Norwegian cancer researchers. Release

> Proteome Sciences is presenting two new biomarker assays at the Alzheimer's conference this week. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.